Peptides in Ottawa: The Federal Regulatory Framework, Stated Plainly

The federal directorate that enforces Canada’s drug law against unauthorized health products has a street address, and it is here: 200 Eglantine Driveway, Tunney’s Pasture — the address published for Health Canada’s Health Product Compliance Directorate, four kilometres west of Parliament Hill. That proximity changes nothing about the law for anyone in Ottawa; the law is the same in Kelowna. It is simply why this is the page where the whole of this site answers the legal question once and properly, instead of thirteen times badly.

Every source below is linked so you can read it rather than take our characterisation of it. Statutory references and government sources were checked against the official texts in August 2026. This is not legal advice, and nothing here says your situation is lawful. For that you need a lawyer, not a supplier.

What the Food and Drugs Act actually says

Section 2 of the Food and Drugs Act defines a drug as including “any substance or mixture of substances manufactured, sold or represented for use in” the “diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state, or its symptoms, in human beings or animals” or in “restoring, correcting or modifying organic functions in human beings or animals.”

The operative words are manufactured, sold or represented for use in. The definition does not turn on chemistry: a compound is not a drug because of what it is, but because of what it is sold and represented for. That clause is the hinge the whole subject swings on. The same section defines “sell” to include distributing “to one or more persons, whether or not the distribution is made for consideration” — giving material away is selling it.

The rest is short. Section 29.1 lets the Minister of Health establish the Prescription Drug List, a list of medicinal ingredients requiring a prescription when found in a drug. Section C.01.014(1) of the Food and Drug Regulations provides that “No manufacturer shall sell a drug in dosage form unless a drug identification number has been assigned for that drug.” Section 9(1) prohibits selling or advertising a drug “in a manner that is false, misleading or deceptive,” and section 3(1) prohibits advertising one to the public as a treatment, preventative or cure for anything in Schedule A.1. None of those has a research-chemical carve-out. Exemptions exist — clinical trial material under Division 5, and C.01.014(2) excludes a “study drug” as defined in C.03.301 — but they are authorization pathways with sponsors and record-keeping attached, not a labelling convention.

The advisory of 9 April 2026, quoted rather than summarised

On 9 April 2026 Health Canada published “Think twice before injecting peptides bought online: unauthorized products can seriously harm you”, naming BPC-157, CJC-1295, DSIP, Epitalon, GHK-Cu, HCG, Ipamorelin, KPV, Melanotan I and II, MOTS-C, NAD+, SS-31, TB-500 and retatrutide. Three passages carry the weight, and they are short enough to reproduce. On classification: In Canada, peptides are generally regulated as prescription drugs. On status: Unauthorized drug products are illegal in Canada and have not been assessed for safety, efficacy, and quality by Health Canada. And on the labelling convention this industry is built on: Health Canada continues to identify products marketed as ‘For Research Use Only – Not for Human Consumption.’ This type of labelling does not make these products legal or exempt from regulatory requirements.

The third is the one that matters, and it is aimed at suppliers like us as much as at anyone. There is no reading of it under which printing a disclaimer converts an unauthorized drug into something that is not one.

What a court ordered in June, and Health Canada announced in July

Enforcement is not theoretical. On 29 July 2026 Health Canada announced that the Superior Court of Québec had, on 11 June 2026, granted it a permanent injunction against Canlab Research and its representatives — order and announcement seven weeks apart, which is why the same event gets dated to both months. It prevents the company and its representatives from manufacturing, testing, distributing or selling unauthorized injectable peptides, from assisting others in doing so, and from advertising those products through websites or social media platforms accessible from Canadian IP addresses. Health Canada had earlier issued a Ministerial Order directing the company to stop, and had warned the public in December 2023 and April 2026.

Two details deserve pulling out: the advertising prohibition is drawn around accessibility from Canadian IP addresses rather than where a company or server sits, and Canlab was a Québec-based domestic seller, not an importer.

The border is a separate question from the counter

The April advisory states that Health Canada has seized several unauthorized injectable peptide drugs and is working with the Canada Border Services Agency to stop unauthorized shipments from entering the country. That is a real mechanism, and it gets overstated in both directions. The CBSA is not the decision-maker: under CBSA Memorandum D19-9-1, which sets out how the agency administers Health Canada’s legislation at the border, it “may detain goods under the authority of the Customs Act and refer them to Health Canada for an admissibility recommendation and disposition decision.” The officer screens and holds; the regulator decides.

So an imported parcel passes a checkpoint at which it can be examined, detained and referred, and a parcel moving between two Canadian addresses does not. That is a genuine, material difference — and the honest version of a claim this industry habitually inflates. It is not a difference in the law. The Food and Drugs Act applies to a sale inside Canada exactly as it applies to an import, and the injunction above was obtained against a domestic seller. Shipping from within Canada removes a customs step. It does not remove the statute.

Where the line between research material and a product for human use falls

Back to that phrase from section 2: manufactured, sold or represented for use in. What decides whether something is handled as a drug is the purpose it is sold and represented for — the surrounding context, not one line of type on a vial. A “for research use only” label is evidence about that purpose, and weak evidence, precisely because printing it costs nothing. Where everything around the label points at human use, the label is contradicted by its own context. What separates the two situations in practice is behaviour rather than typography, and a reader can check all of it:

• whether the seller publishes administration guidance, protocols or human-use quantities anywhere on its site, including in blog posts and tools;
• whether it makes or implies therapeutic claims, including carefully hedged ones;
• whether product pages are written around human outcomes or around analytical characterisation;
• whether it answers a human-use question when asked one, or declines;
• whether lot-level analytical documentation exists at all — which a research buyer needs and a consumer has no use for.

Doing all of that consistently is still not authorization, and we will not imply that it is. It is the difference between a supply operation aimed at laboratories and a consumer health product wearing a disclaimer — and Health Canada’s position, that the disclaimer alone does not do the work, is correct. That is an uncomfortable sentence for a supplier to write, and the reason it is worth writing.

There is no provincial layer

Every other city page on this site links here for the legal question, and this is why: there is nothing local to say. The Food and Drugs Act and its Regulations are federal, the Prescription Drug List is maintained by the federal Minister of Health, the Controlled Drugs and Substances Act is federal, the CBSA is federal. There is no Ontario research-chemical statute, no Alberta permit, no British Columbia registry. A page telling you the rules in Winnipeg differ from those in Halifax has invented them. Three things do vary by province, and not one is a regulatory regime:

• Sales tax. Ontario applies a single combined 13% HST, the federal 5% sitting inside that rate rather than added to it; Alberta is 5%, British Columbia 12%, Quebec 14.975%. We publish no landed-cost figures, because whether an item is taxable is a determination separate from the rate and we have not confirmed it.
• Quebec’s French-language obligations, which attach to commercial documentation in Quebec and nowhere else, and are handled on our pages for Montreal and Quebec province and Québec City.
• Health-authority structure. British Columbia organises care delivery through regional health authorities — administrative, not a rule about what may be sold.

That is the complete list. The rest of Ontario gets the same federal answer, which is why our Toronto page covers purchasing documentation and our Hamilton and Waterloo Region page covers that corridor’s institutions instead.

The research city underneath the regulatory one

Ottawa holds the federal health regulator, the federal government’s principal research organization and a substantial university-and-hospital research base inside one metropolitan area. The National Research Council’s head office is at 1200 Montreal Road, and its Human Health Therapeutics Research Centre works from the same campus, in Building M-54, on biologics and vaccines — antibody-based therapeutics, bioprocess development, cell and gene therapy.

An earlier version of this page said that centre conducts peptide therapeutics research, making the NRC a significant consumer of research-grade peptide material. We checked, and the correction is worth making in public: the NRC’s own descriptions of the centre and its scientists do not use the word peptide, describing biologics, vaccines, immunobiology and antibody work instead. The observation underneath survives in a more careful form. Antigen design, immunoassay development and analytical method validation consume synthetic peptides as reagents and reference standards wherever they are done, and institutional programmes of that kind are the real demand base for research-grade peptide material in this country — a statement about a field, not about anyone’s purchase orders. No institution named here is a customer, partner or affiliate of ours.

The rest, verified August 2026: the University of Ottawa, which describes itself as “the largest bilingual (English-French) university in the world” and reports roughly 48,000 students; the Ottawa Hospital Research Institute, research arm of The Ottawa Hospital and an affiliated institute of the university, reporting 2,399 scientists, investigators, trainees and staff (an older “over 1,800 staff” figure sat on this page and is out of date); the University of Ottawa Heart Institute; the CHEO Research Institute; Carleton University.

What we do, and what we are not going to claim

We are not going to tell you this store is “fully compliant” or “Health Canada approved.” Neither is true, and the April advisory closes that escape route explicitly. A supplier whose response is to repeat the labelling convention more loudly has not answered it.

What we can state is what we do. We supply these compounds as laboratory research materials. Every lot is independently tested — HPLC‑UV for purity, mass spectrometry for identity — and the batch-specific certificate is published before the lot goes on sale, with the lot number on the vial; for what a useful certificate contains, we keep a guide to reading one. We publish no dosing, administration, injection, or preparation guidance of any kind, and we do not provide it on request. Nothing on this site tells anyone how to use these compounds in a person, because they are not supplied for that purpose. We make no therapeutic claims. Several compounds named in the 9 April advisory are ones we list — retatrutide, BPC-157 and GHK-Cu among them — and pretending otherwise on the page where we discuss the advisory would be ridiculous. What we will not do is tell you where you stand: that is the one thing a supplier is least qualified to say and most motivated to get wrong.

Regulatory status and research-use position

On 9 April 2026, Health Canada published a public advisory, “Think twice before injecting peptides bought online: unauthorized products can seriously harm you,” naming retatrutide, BPC-157, CJC-1295, GHK-Cu, MOTS-C, TB-500 and other compounds. The advisory states that peptides of this kind are generally regulated as prescription drugs in Canada, that unauthorized drug products are illegal, and — addressing the labelling convention this industry relies on directly — that this type of labelling does not make these products legal or exempt from regulatory requirements. On 11 June 2026 the Superior Court of Québec granted Health Canada a permanent injunction against a Canadian seller of injectable peptides; Health Canada announced it publicly on 29 July 2026. Enforcement is active.

Our position is unambiguous. ThePeptide supplies these compounds as laboratory research materials only. They are not approved by Health Canada for human or veterinary use, and they are not sold for those purposes. We make no therapeutic claims. We publish no dosing, administration, injection, or preparation guidance of any kind, and we do not provide it on request. Nothing on this site tells anyone how to use these compounds in a person, because they are not supplied for that purpose. Nothing we supply is intended for human consumption, injection, veterinary use, diagnostic use, cosmetic use, or therapeutic application.

If you are considering these compounds for personal health reasons, the advisory is addressed to you and you should read it before going further: Health Canada public advisory, 9 April 2026. Speak to a licensed healthcare practitioner.

What we do commit to, for the laboratory-research market we serve: every lot is independently tested by HPLC‑UV for purity and by mass spectrometry for identity, and the batch-specific Certificate of Analysis is published before the lot goes on sale, with the lot number printed on the vial.

Questions about the federal framework

Does “for research use only” labelling make a peptide legal to sell in Canada?

No, and Health Canada has said so in terms: This type of labelling does not make these products legal or exempt from regulatory requirements. The reason sits in the statute. Section 2 of the Food and Drugs Act defines a drug by what a substance is “manufactured, sold or represented for use in” — a question about the whole commercial context, not one line of small print. A disclaimer is evidence of purpose, and weak evidence, because printing it costs nothing.

Health Canada is headquartered in Ottawa. Does that change anything about an order delivered here?

No. Proximity to the regulator is not a regulatory fact. The Food and Drugs Act, its Regulations, the Prescription Drug List and the Canada Border Services Agency all operate nationally, and an Ottawa address is treated identically to one in Kamloops. What Ottawa gives this page is a reason to exist rather than a rule: the department that administers the statute sits here, at Tunney’s Pasture.

What exactly did the Canlab Research injunction prohibit?

The Superior Court of Québec granted it on 11 June 2026; Health Canada announced it on 29 July 2026. It prevents Canlab Research and its representatives from manufacturing, testing, distributing or selling unauthorized injectable peptides, from assisting others in doing so, and from advertising those products through websites or social media platforms accessible from Canadian IP addresses. Health Canada has said it may refer the matter for prosecution or apply for a finding of contempt.

My delivery address is in Gatineau, across the river. Is anything different?

The federal position is identical, because it is federal. Two things change at the bridge: the order is taxed at Quebec’s combined 14.975% rather than Ontario’s 13%, the highest rate of any province we ship to, and Quebec’s French-language requirements apply to commercial documentation there. The parcel is a domestic Canadian shipment either way — the Ottawa River is a provincial boundary, not a customs one.

Can you tell me whether what I am doing is legal?

No. This page describes the federal framework and links the primary sources so you can read them yourself, and that is the limit of it. It is not legal advice and not an opinion about your circumstances, and a supplier is the worst-placed party to offer one, having a commercial interest in the answer. Ask a lawyer. If you are considering these compounds for personal health reasons, the 9 April 2026 advisory is addressed to you.